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Despite early detection and reduced risk of death, prostate cancer still remains the second
leading cause of cancer death in American men. There is currently no cure for advanced
prostate cancer. The multistage, stochastic and highly heterogeneous nature of prostate
cancer, coupled with genetic and epigenetic alterations that occur during disease progres-
sion and response to therapy, represent fundamental challenges in our quest to understand
and control this complex and prevalent disease. Recent advances in drug development and
breakthroughs in omics technologies have renewed our efforts to identify novel biomark-
ers for prostate cancer prognosis, prediction, and therapeutic response monitoring. In
this perspective article, we overview the current status and highlight future prospects of
biomarkers for prostate cancer, a disease that affects millions of men worldwide.
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INTRODUCTION
The incidence of prostate cancer has increased dramatically in
recent years, largely because of an aging population, the prac-
tice of prostate-speciﬁc antigen (PSA) testing and subsequent
biopsy. In the United States, prostate cancer is the most com-
monly diagnosed cancer in men and second only to lung cancer in
the number of cancer deaths, with a total of 241,740 new cases
and 28,170 deaths from prostate cancer projected to occur in
2012 (Siegel et al., 2012). Worldwide, prostate cancer is the sec-
ond most prevalent cancer diagnosis and the sixth leading cause
of death from cancer in men, with a global incidence of 913,000
new cases and 258,000 deaths in 2008, according to the WHO
GLOBOCAN database. Effective therapeutic options are available
for early stage prostate cancer. However, despite the recent advent
of anticancer agents, there is still no cure for the advanced stage of
the disease. This article presents amultidisciplinary perspective on
the role of biomarkers in prostate cancer drug development and
patient care.
TYPES OF BIOMARKERS
The National Cancer Institute deﬁnes a biomarker as “a biological
molecule found in blood, other body ﬂuids, or tissues that is a sign
of a normal or abnormal process, or of a condition or disease.”
Based on biological properties, biomarkers may also be speciﬁc
cells, molecules, or genes, gene products, enzymes, or hormones
etc (Biomarkers Deﬁnitions Working Group, 2001). For the pur-
poses of developing drugs, three key types of biomarkers are used
to guide clinical development – prognostic, predictive, and phar-
macodynamic (PD) – each of which can inﬂuence decisionmaking
and aid in the rational development of anticancer agents. Prog-
nostic biomarkers inform the natural course of the cancer in the
absence of therapy or on standard chemotherapy regimens, distin-
guishing those patients with tumors that result in “good outcome”
versus those with a “poor outcome.” They can be used to guide
decisions of whom to treat, and how aggressively to treat. Predic-
tive biomarkers differ in that they are used to identify (predict)
those patients who are most likely to beneﬁt from a particular
treatment, enabling “personalized medicine.” PD biomarkers are
used to assess the post-treatment effects of a drug on a tumor,
conﬁrm target or pathway modulation and mechanism of action,
and can, at times, be used to guide or at least, increase conﬁdence
in the dosage that should be used in subsequent proof of concept
and pivotal trials.
THE QUEST FOR PROSTATE CANCER BIOMARKERS
ACTIVE SURVEILLANCE VERSUS CHEMOPREVENTION
Prostate cancers display a variable range of clinical behaviors, from
slow-growing tumors of no or little clinical signiﬁcance, to aggres-
sively metastatic and lethal diseases. In addition to improved
cancer registries and transurethral prostatectomy, population-
based PSA screening has been postulated to contribute to the
increased incidence of prostate cancer, causing “over-diagnosis,”
where a large number of detected prostate tumors are indo-
lent. Aggressive treatment in patients with indolent diseases can
result in side effects and reduce a patient’s quality of life for
little to no beneﬁt. One of the current clinical priorities is to
develop prognostic biomarkers to identify those with indolent
prostate diseases at low risk of progressing, so that these patients
may better beneﬁt from active surveillance or watchful wait-
ing, thus avoiding unnecessary treatment and ﬁnancial burden
(Figure 1).
Our extensive knowledge of the etiology and progression
of prostate cancer also makes it an ideal disease for cancer
prevention. Androgen deprivation is the natural choice for pre-
vention because of the established hormonally mediated patho-
genesis for prostate diseases. However, chemoprevention with
5α-reductase inhibitors (5-ARI) has yielded encouraging yet
ultimately confounding results in two landmark randomized,
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FIGURE 1 | Types of biomarkers in prostate cancer prognosis,
therapeutic response, and drug development. Biomarkers can be used to
predict the natural course of a prostate disease (prognosis), help clinicians
with decision making about the likelihood to respond to a given drug
(predictive) and at what dose it might be most effective (pharmacodynamics).
Red color denotes types of biomarker, blue color denotes the
biomarker-based decision making, and green color indicates the exemplary
actions or events. PSA, prostate-speciﬁc antigen; DRE, digital rectal
examination; TRUS, transrectal ultrasound; PD biomarker, pharmacodynamic
biomarker.
placebo-controlled prostate cancer prevention trials (Thompson
et al., 2003; Andriole et al., 2010); it decreased the overall inci-
dence of prostate cancer yet increasing the risk of developing
high-grade prostate cancer in certain patients. The lingering
uncertainty surrounding the risk of disease progression has
thus far discouraged FDA approval (Walsh, 2010), while high-
lighting the necessity of identifying predictive biomarkers to
discriminate between those who may or may not beneﬁt from
chemoprevention.
CANCER TREATMENT AND DRUG RESISTANCE
Regardless of our current experience with PSA, early detection
remains essential in treating clinically relevant prostate cancer.
Localized prostate cancer, a tumor conﬁned to the prostate
gland, may be treated effectively with prostatectomy, radiation
therapy, or other local treatments (Figure 1). For advanced
prostate cancer that has recurred or spread beyond the prostate
to lymph nodes, bones, or other sites, androgen deprivation
therapy (ADT) remains the “gold standard” treatment, which
yields considerable clinical beneﬁts. However, similar to the
development of acquired resistance in melanoma patients treated
with Vemurafenib, most prostate cancer patients who initially
respond to ADT subsequently become refractory. Ampliﬁcation
or mutations in androgen receptor (AR), AR-PI3K cross talk,
reactivation of TMPRSS2:ERG fusion and the androgen-response
pathway, and epithelial to mesenchymal transition (EMT) have
been reported in castration-resistant prostate cancer (CRPC;
Amler et al., 2000; Yap et al., 2011; Sun et al., 2012). Unlike
KRAS mutations that are used to predict primary resistance to
epidermal growth factor receptor (EGFR) targeted therapy in
metastatic colorectal cancer, no biomarker has yet been identi-
ﬁed to predict resistance to ADT in prostate cancer. Therefore, an
improved understanding of molecular mechanisms of acquired
resistance to ADT may provide valuable insights to enhance
the efﬁcacy of standard-of-care therapeutic intervention. The
recent identiﬁcation of AR splicing variants associated with
acquired resistance to ADT in prostate cancer patients represents
a landmark conceptual advancement in the prostate cancer ﬁeld
(Hu et al., 2010).
Very recently, there has been a rapid increase in the num-
ber of effective systemic agents for men with metastatic CRPC
(mCRPC), including abiraterone acetate and MDV3100 (hor-
monal therapies), Sipuleucel-T (immunotherapy), Cabazitaxel
(chemotherapy), Denosumab, and Radium 223 (bone microen-
vironment targeting agents; Armstrong et al., 2011). How-
ever, the high cost of these therapies, genetic heterogeneity
of prostate cancer, and the increasing complexity of clini-
cal decision making, have highlighted the need for effective
biomarkers to identify the right therapy for the right patient
and enable the monitoring of therapeutic response and disease
progression.
CURRENT STATUS OF PROSTATE CANCER BIOMARKERS
PROTEIN BIOMARKERS
Human prostatic acid phosphatase (PAP) was reportedly the
ﬁrst, though less sensitive, serum biomarker for prostate cancer
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(Gutman and Gutman, 1938). Recent advancements in pro-
teomics, tissue microarray, and other biotechnologies have led
to many protein biomarkers being reported, including, among
others, chromogranin-A, interleukin-6, and prostate-speciﬁc cell
antigen (Makarov et al., 2009; Madu and Lu, 2010). Here we will
discuss, PSA, the current “gold standard” biomarker for prostate
cancer.
Prostate-speciﬁc antigen, a 33 kDa serine protease produced
by both normal and neoplastic prostate epithelial cells, belongs
to the family of “Kallikrein genes.” The introduction of PSA
has revolutionized prostate cancer screening, and PSA testing is
currently a standard clinical application for staging and measur-
ing disease progression and therapeutic response. Despite these
advances, considerable debate still remains. The ﬁrst and most
important concern is the lack of cancer speciﬁcity as the rise
in PSA level can reﬂect the presence of non-malignant disor-
ders such as benign prostatic hyperplasia, infection, or chronic
inﬂammation. Further, changes in the epidemiology of prostate
cancer limit the correlation between PSA and the stage of prostate
cancer where signiﬁcant numbers of men with “normal” or very
low PSA values may nonetheless harbor prostate cancer (Thomp-
son et al., 2004). Moreover, the level of PSA expression appears
to be inversely correlated with higher Gleason scores in cer-
tain studies (Aihara et al., 1994; Darson et al., 1997). As such,
the United States Preventative Services Task Force has recently
published draft recommendations against PSA-based prostate
cancer screening. In the meantime, the concept of using PSA
as a PD biomarker in therapeutic interventions is also chang-
ing, as evidenced by a lack of PSA response in CRPC patients
receiving Sipuleucel-T, an immunomodulatory agent that pro-
longs life and is postulated to slow disease trajectory in part
through effects on the prostate tumor microenvironment (Gul-
ley and Drake, 2011). Taken together, serum PSA levels must be
interpreted carefully and algorithms or nomograms that com-
bine disease stage, grade, circulating tumor cells (CTCs), and
PSA level for an individual patient rather than PSA alone should
be used.
CIRCULATING TUMOR CELLS
Circulating tumor cells, which are rare in healthy adults, originate
from the primary tumor or metastatic deposits after invading and
intravasating through the tumor vasculature. It has been shown
that CTCs isolated from patients with mCRPC exhibit features of
prostate cancer, expressing PSA and alpha-methylacyl-CoA race-
mase (AMACR), and exhibiting genomic abnormalities such as
AR ampliﬁcation, PTEN loss, and TMPRSS:ETV fusion (Attard
et al., 2009). Studies have shown that the enumeration of CTCs
fromwhole blood is prognostic for overall survival inmany tumor
types including mCRPC (de Bono et al., 2008; Danila et al., 2011).
In addition to providing prognostic information and a potential
indicator of efﬁcacy, CTCs also have the potential to provide a real-
time snapshot of the molecular makeup of an individual patient’s
tumor, to proﬁle for determinants that predict for sensitivity or
resistance to therapy (Punnoose et al., 2010). Enumeration of
CTCs – as measured by the CellSearch assay – has been cleared by
the FDA for use as an aid tomonitormenwithmCRPC in conjunc-
tion with other clinical assessments of response/beneﬁt. Efforts
are ongoing to qualify the measurement of CTCs for determining
patient response and drug efﬁcacy in mCRPC.
GENOMIC BIOMARKERS
Genomic biomarkers measure DNA or RNA characteristics that
are indicative of biologic processes, disease progression, and/or
response to therapeutic interventions. At the DNA level, genetic
and epigenetic alterations are common events in prostate cancer.
Recent genomics studies have shown promise in being able to sub-
type prostate tumors for diagnostic purposes by using genomic
classiﬁcation. Taylor et al. (2010) used an integrative genomic
analysis to identify copy number variation as a biomarker to pre-
dict prostate cancer outcome. Ding et al. (2011) used comparative
oncogenomics to derive a four-gene signature and an additional
pathway-representative fourteen-gene panel that proved superior
as a prognostic biomarker compared to PSA (Ding et al., 2012).
Similarly, a population-based study demonstrated the use of a
ﬁve-SNP panel to predict aggressive prostate cancer (Lin et al.,
2011). At the epigenetic level, methylated genes including GSTP1,
DNMT3A2, and EZH2 are emerging as attractive biomarkers
for prostate cancer (Henrique and Jeronimo, 2004; Kobayashi
et al., 2011).
At the level of gene transcription, genomic biomarkersmeasure
RNA characteristics including, but not limited to, protein-coding
gene expression, RNA processing (splicing and editing), and non-
coding RNAs including small (microRNAs, snoRNAs) and long
RNAs (antisense RNA, dsRNA, and long RNA species). Recent
attempts to stratify or cluster prostate cancers on the basis of
RNA gene signature and/or histology have yielded disappointing
results, despite its proven success in breast cancer (Hegde et al.,
2007). More recently, Tomlins et al. (2011) demonstrated that
urine TMPRSS2:ERG fusion transcript, in combinationwith urine
PCA3, a prostate cancer-speciﬁc non-coding mRNA, enhances
the utility of serum PSA for predicting prostate cancer risk and
clinically relevant cancer on biopsy.
Among the non-coding RNAs, microRNAs are small (an
average of 22 nucleotides), single-stranded, highly conserved
RNA molecules that repress gene expression in a sequence-
dependent manner. In prostate cancer, deregulated microRNA
expression correlates with clinically aggressive or metastatic can-
cer phenotypes (Tavazoie et al., 2008; Bryant et al., 2012), where
circulating microRNAs such as miR-141 distinguish patients with
prostate cancer from healthy controls (Mitchell et al., 2008) and
miR-21predicts the resistance to docetaxel-based chemotherapy in
patients with mCRPC (Zhang et al., 2011). Currently, microRNA
gene signatures are being evaluated in prostate cancer clinical trails
(e.g., NCT01050504). The fact that microRNAs remain stable and
detectable in archival, especially formalin-ﬁxed parafﬁn embed-
ded (FFPE) tissues, and in body ﬂuids has made them attractive
candidates as cancer biomarkers.
mRNAs andmicroRNAs are also detected in exosomes, the 30–
100 nm membrane vesicles that are secreted by multiple cell types
and detectable in blood, urine, amniotic ﬂuid, and malignant
ascites (Valadi et al., 2007; Mitchell et al., 2008). Recent studies
demonstrate that the circulating exosomal microRNA signatures
parallel the developmental origins of tumor cells (Taylor and
Gercel-Taylor, 2008), and increased levels of exosomes found in
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blood of patients with late-stage prostate, ovarian, and lung cancer
suggests a role for thesemembrane vesicles in cancer diagnosis and
biomarker analysis (Duijvesz et al., 2011).
METABOLOMICS AND IMAGING BIOMARKERS
Metabolomics has recently emerged as a novel approach to early
and non-invasive prostate cancer detection based on changes in
the metabolic signatures, including citrate, polyamines, lactate,
choline, and creatine (Spratlin et al., 2009; Roberts et al., 2011), in
addition to sarcosine and alanine (Tessem et al., 2008; Sreekumar
et al., 2009).
The ﬁeld of imaging in prostate cancer care is continuously
evolving. FDG-PET imaging, whichmeasures the extent of change
in glucose utilization in many cancer types, appears to be associ-
ated with increasing Gleason grade, clinical stage, and serum PSA
level (Jadvar, 2009). ImmunoPET imaging for antibody drug con-
jugates offers exciting potential diagnostic applications (Nakajima
et al., 2011). The routine clinical use of transrectal ultrasound,
magnetic resonance imaging (MRI), computed tomography (CT),
radionuclide bone scanning, and positron emission tomography
(PET) in prostate cancer has been described in excellent reviews
(Hricak et al., 2007; Pinto et al., 2012).
However, the biomarkers mentioned above are based on rel-
atively small cohorts of patients and the results merit further
prospective validation.
ARCHIVAL TISSUES IN PREDICTIVE DIAGNOSTICS
Clinical decision for prostate cancer often relies on the initial diag-
nostic tumor biopsy. However, such archival tissues may not be
representative of the mutational landscape of the entire tumor
bulk due to intratumor heterogeneity. They often do not carry
the genomic alterations accumulated in the metastatic deposits,
which may arise years later. Fresh biopsies would be preferable
but obviously are difﬁcult to obtain in mCRPC, given its partic-
ular propensity to metastasize to bone and induce blastic bone
lesions. Surrogate biomarkers, such as CTCs, circulating tumor
DNA, and microRNA,may serve as a non-invasive “liquid biopsy”
to complement the use of archival tissues and PSA for predictive
diagnostics.
PERSONALIZED CANCER THERAPY
The landmark discoveries of Trastuzumab in breast cancer and
Imatinib in chronic myeloid leukemia (CML) have opened the
door to personalized medicine, treating patients individually by
targeting the pathways that are present or activated in their tumors.
In this regard, biomarker-based patient stratiﬁcation is a key fac-
tor toward the development of targeted therapeutics for prostate
cancer (Figure 1).
The PI3K-PTEN signaling pathway is a noteworthy example.
PTEN loss of function has been observed in 40–70% of advanced
prostate cancer, accompanied by frequent alterations in the path-
way network such as INPP4B, PHLPP, and PIK3R1 (Taylor et al.,
2010). The fact that PTEN-null prostate tumors respond to inhi-
bition of PI3K has demonstrated the possible role of PTEN loss
as a predictive biomarker in clinical trials testing PI3K pathway
inhibitors (Jia et al., 2008, 2009; Lackner, 2010). Like other tar-
geted therapies, resistance eventually occurs, leading to treatment
failure. For instance, c-Myc elevation confers resistance to PI3K
inhibitors (Ilic et al., 2011; Liu et al., 2011) and overrides the
mTOR dependence of prostate lesions arising from constitutive
AKT activation (Clegg et al., 2011). More importantly, allelic loss
of PTEN and gain of c-Myc co-exist in 3% (4/126) human prostate
cancer (Zafarana et al., 2012), suggesting innate resistance to PI3K
inhibitors in this type of tumor. Thus, deciphering the genetic
make-up of prostate tumorsmay facilitate patient stratiﬁcation for
PI3K targeted therapies. In deed, biomarker-driven drug devel-
opment has been encouraged by the regulatory authorities as
exempliﬁed by the fast-track approval of Trastuzumab for the
treatment of Her2-positive breast cancer.
WHEN PROSTATE MEETS OMICS: THE NEXT-GENERATION
BIOMARKERS
The breakthroughs of omics-based technology development have
revolutionized drug development and cancer care for prostate can-
cer. The enormous deluge of omics data generated over the past
5 years has easily surpassed the sum of wet bench data from the
past several decades, providing unprecedented opportunities to
re-visit the long-standing problem of biomarker development in
prostate and other common human cancers. The use of proteomic
technologies in micro-dissected clinical specimens would help to
reveal the intricate tumor-stroma signaling networks that cross-
talk in prostate cancer. Massively parallel sequencing technologies,
in particular, the applicationof next-generation sequencing (NGS)
of matched localized prostate tumors and mCRPC, coupled with
genetic and epigenetic proﬁling, have vastly improved our capac-
ity to more comprehensively uncover the multistage, stochastic
and highly heterogeneous nature of prostate cancer. The recent
identiﬁcation of AR splicing variants in CRPC is an excellent
example of NGS-driven prostate cancer biomarker discovery
(Hu et al., 2010).
The considerable challenge that remains is the functional inter-
pretation of the genetic and epigenetic changes derived from the
vast amounts of omics data. The sophisticated computational
algorithms and systems biology approach that are currently being
explored will aid in the identiﬁcation of the driving oncogenic
events from passenger events, deriving novel biomarkers to detect
and guide the treatment of prostate cancer.
PERSONALIZED CANCER PREVENTION
Despite the advent of new cancer therapies, the future of prostate
cancer care will depend on early detection and effective can-
cer prevention. Targeted or personalized therapy is increasingly
becoming part of clinical practice for many types of advanced
cancers, however, this approach has not been adopted in the
setting of prostate cancer prevention, where certain oncogenic
events already occur at the very early stage of prostate cancer.
The recent breakthroughs in decoding the “$1,000 genome” have
renewed our efforts to identify novel biomarkers to sub-classify
prostate cancer patients and prevent prostate cancer with a more
targeted or “personalized” approach. Here we propose the concept
of “biomarker-driven, personalized prevention of prostate can-
cer,” where biomarkers will guide the clinical decisions of whom
to treat and which molecularly targeted intervention to be used
(Figure 2).
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FIGURE 2 | Black boxes denote conceptual breakthroughs, blue boxes
denote biomarker advances, and green boxes denote therapeutic
and technological outlook. PAP, prostatic acid phosphatase; PSA,
prostate-speciﬁc antigen; FDA, US Food and Drug Administration; CTC,
circulating tumor cells; NGS, next-generation sequencing; miRNA,
microRNA.
CLOSING REMARKS
Prostate cancer is poised to enter a new era of personalized health
care, where biomarkers act as a central hub in cancer detection,
treatment, and prevention. The next breakthroughs in therapeu-
tics and biomarkers will only occur with an in-depth understand-
ing of fundamental disease mechanisms, such as prostate cancer
initiation and progression, response to therapy, and mechanisms
of action of anticancer agents. Such “disease orientation” will
require a greater collaboration between industry, academia, reg-
ulatory agencies, and patients. The integrative, interdisciplinary
systems biology approach, armed with omics technologies, is
offering promise in the quest of next-generation biomarkers.
In the coming decades, the identiﬁcation, qualiﬁcation, and
application of novel biomarkers will remain as the aspiration of
patient care and the drug discovery paradigm for prostate cancer.
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